Stem Cell, Tissue Engineering and Nanomedicine
|
|
Submission deadline: 08/31/2016
|
Scope and purposes
|
Tissue and organ regeneration is a fast emerging field with implications in repair of injuries, regenerating a new tissue and replacement of defects. Stem cells (SC), which are primitive in nature, have great potential in this regard owing to their totipotency, pluripotency and multipotency. Nowadays, the combination of SC and tissue regenerating biomaterials are being tested for repair and regeneration of defective organs. The biomaterials based scaffolds are designed at nanoscale (10-9m) to improve their biocompatibility and reduce time for tissue growth. The special issue in this theme will solicit new ideas and research being carried out in this advanced filed to update the esteemed readers of Scientific and Academic Publishing.
|
Topics of primary interest include, but are not limited to:
|
• Stem Cells • Tissue Engineering • Biomaterials • Nanomedicine • Bioconjugation • Encapsulation • Regenerative medicine
|
Important Dates
|
Deadline for submission:
08/31/2016
|
Deadline for
revision:
11/30/2016
|
Notification of final decision:
12/31/2016
|
|
Estimated Publication:
January 2017 (Tentative)
|
Submission
|
Abstracts addressing one or more of these themes/topics or further questions should be emailed to an editor by <08/31/2016> at yog_verm@rediffmail.com and yog.kverma@gmail.com. Manuscript submissions are invited by the submission deadline. All papers will undergo a double or triple-blind peer review process.
|
Guest Editors
|
Dr. Yogesh Kumar VermaPh.D. Institute of Nuclear Medicine and Allied Sciences (INMAS) yog_verm@rediffmail.com
|
Manuscript submission deadline
08/31/2016
|
|
Metabolomics between Toxicology and Medicine
|
|
Submission deadline: 09/14/2015
|
Scope and purposes
|
The aim of this Special Issue of American Journal of Biochemistry is to bring together the biochemistry researches applied in toxicology and medicine, using metabolic profiling and products as references. This Issue is related to animals, plants and human metabolomics; having in view the action of some compounds or products that are essential for the living organism in right amounts or, once arrives in the living organism in high concentrations disturb the normal biochemical profile. Since ancient times, people used different plants and natural extracts to prevent or treat various diseases, but the dose was essential. Thus, some of bioelements or biocompounds are essential for living organism being useful for a good health status, but overdoses can produce toxic effects. Metabolomics is referring to target metabolite analysis, with applications in toxicology (intoxications or overdoses), medicine, and molecular biology.
|
Topics of primary interest include, but are not limited to:
|
• Clinical Biochemistry • Analytical Biochemistry • Toxicology • Molecular biology • Human Medicine • Veterinary Medicine • Plant Biology
|
Important Dates
|
Deadline for submission:
09/14/2015
|
Deadline for
revision:
10/14/2015
|
Notification of final decision:
10/28/2015
|
|
Estimated Publication:
11/30/2015 (Tentative)
|
Submission
|
Abstracts addressing one or more of these themes/topics or further questions should be emailed to an editor by <09/14/2015> at mirelaahmadi@yahoo.com, mirelaahmadi@usab-tm.ro. Manuscript submissions are invited by the submission deadline. All papers will undergo a double or triple-blind peer review process.
|
Guest Editors
|
Mirela AHMADILecturer, PhD, Department of Biochemistry and Molecular Biology, University of Agricultural Sciences and Veterinary Medicine of Banat, Timisoara, Romania mirelaahmadi@yahoo.com, mirelaahmadi@usab-tm.ro
|
Manuscript submission deadline
09/14/2015
|
|
Evaluation of biochemical aspects of infectious diseases
|
|
Submission deadline: 02/12/2013
|
Scope and purposes
|
The aim of this special issue is to provide the latest evidence of the biochemical role of infectious disease and their impacts on health. The special issue will focus on providing long-term trends based on evaluation of biochemical approach on infectious diseases. It will also welcome case studies of such studies providing the best available evidence. Recent technological advances, especially in the fields of proteomics, have given patients and doctors new hope for a different approach to detecting and treating infectious disease. The validation of biomarkers of infectious disease is also quite challenging, and many questions have been raised regarding how new tests will be developed, evaluated, and integrated into clinical practice. We are interested in this special issue by papers covering all aspects of infectious disease, validation, and qualification in diagnosis, therapy and prognosis.
|
Topics of primary interest include, but are not limited to:
|
• Infectious disease biomarker development and validation • Role of ROS in infectious diseases • Proteomics approach for the elucidation of infectious disease • Screening and predictive analysis of infectious disease • Infectious diseases and cancer
|
Important Dates
|
Deadline for submission:
02/12/2013
|
Deadline for
revision:
05/03/2014
|
Notification of final decision:
10 /03/2014
|
|
Estimated Publication:
2014 (Tentative)
|
Submission
|
Abstracts addressing one or more of these themes/topics or further questions should be emailed to an editor by <02/12/2013> at sshaq2002@yahoo.co.in Manuscript submissions are invited by the submission deadline. All papers will undergo a double or triple-blind peer review process.
|
Guest Editors
|
Dr.S.S.Haquesshaq2002@yahoo.co.in
|
Manuscript submission deadline
02/12/2013
|
|
Cancer biomarkers in diagnosis and treatment: Recent advances
|
|
Submission deadline: 02/05/2013
|
Scope and purposes
|
Cancer biomarkers have contributed greatly to our current understanding of the heterogeneous nature of specific cancers and have led to improvements in earlier diagnosis and treatment outcomes; nevertheless its application is still controversial. There are thousands of cancer-related biomarker references in the literature, but only a handful of oncology biomarkers have been validated for clinical use.
Recent technological advances, especially in the fields of genomics and proteomics, have given cancer patients and doctors new hope for a different approach to detecting and treating cancer. The validation of cancer biomarkers is also quite challenging, and many questions have been raised regarding how new tests will be developed, evaluated, and integrated into clinical practice.
We are interested in this special issue by papers covering all aspects of cancer biomarker discovery, validation, and qualification in diagnosis, therapy and prognosis.
|
Topics of primary interest include, but are not limited to:
|
• Cancer biomarker development and validation
• Biomarker in cancer earlier detection.
• Screening and predictive biomarker.
• Molecular biomarker in targeted therapy
|
Important Dates
|
Deadline for submission:
02/05/2013
|
Deadline for
revision:
04/20/2013
|
Notification of final decision:
05/05/2013
|
|
Estimated Publication:
2013 (Tentative)
|
Submission
|
Abstracts addressing one or more of these themes/topics or further questions should be emailed to an editor by <02/05/2013>. Manuscript submissions are invited by the submission deadline. All papers will undergo a double or triple-blind peer review process.
|
Guest Editors
|
Dr. Adel GOURIHead of laboratory of Medical Biochemistry, Ibn Zohr Public Hospital, Guelma,Algeria.pharmagor@gmail.com
Prof. Nabil Mohie AbdelhamidDean of Pharmacy College and Professor of Cancer biology, Pharmacy College Kafrelsheikh University, Egypt.
nabilmohie@yahoo.com
|
Manuscript submission deadline
02/05/2013
|